DARE - Company ID 0001401914
The table below shows Dare Bioscience, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.52M | -$5.47M | -$6.81M | -$16.12M | -$12.34M | -$8.38M |
| Capital expenditure | $0.00 | $157.33K | $7.30K | $0.00 | $4.55K | $0.00 |
| Investing cash flow | $0.00 | -$157.33K | -$7.30K | $0.00 | -$4.55K | $0.00 |
| Dividends paid | - | - | - | - |
Dare Bioscience, Inc. reported operating cash flow of -$9.89M for fiscal year 2025. That is down 280.6% from $5.47M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$2.54M (FY 2017) to -$9.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$715.47K | $246.58K | $14.03K | $1.30M | $0.00 | $11.37M |